Anti-amyloid therapies and the transformation of Alzheimer's care pathways: early lessons from the frontline - PubMed
4 hours ago
- #Alzheimer's disease
- #Anti-amyloid therapy
- #Real-world implementation
- Anti-amyloid monoclonal antibodies represent a significant shift in Alzheimer's disease (AD) treatment, focusing on biological modification.
- The Center for Alzheimer's and Related Diseases (CARD) developed a fast-track pathway for timely and safe access to therapies like lecanemab and donanemab.
- Patient selection for these therapies requires integrating cognitive, functional, and biological data, moving beyond traditional score thresholds.
- Safety monitoring must balance ARIA risk with real-world feasibility through risk-adapted MRI surveillance.
- Effective implementation of these therapies depends on transparent communication and continuous shared decision-making, especially in uncertain benefit or safety scenarios.
- The success of disease-modifying therapies hinges on coordinated care models supported by real-world registries.